FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-028								
Fatimated average	hurdon								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

hours per response: 0.5

Name and Address of Reporting Person* Ciaffoni Joseph						2. Issuer Name and Ticker or Trading Symbol COLLEGIUM PHARMACEUTICAL, INC									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
<u>Ciaffoni Joseph</u>						[COLL]								_	X	Direc	ctor	10	% Owner	
(Last) (First) (Middle)				Ľ	[0022]									X Officer (give title below)				Other (specify below)		
` ′	C/O COLLEGIUM PHARMACEUTICAL, INC.					3. Date of Earliest Transaction (Month/Day/Year) 11/29/2019									President and CEO					
100 TECHNOLOGY CENTER DRIVE																				
(Street)				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)						
STOUGH	HTON M	Α (2072												X		n filed by One			
(0:1)	(0)		- · \												Pers	n filed by Mor on	e than One	Reporting		
(City)	(St	ate) (Zip)																	
		Tabl	e I - No	n-Deriv	ative	Sec	curitie	s Acc	uired,	Dis	posed o	f, or	r Ben	efici	ally	Owne	ed			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da						Execution Date,				ties Acquired (A) d Of (D) (Instr. 3, 4			4 and Secu Bend Own		cially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of Indire	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount		(A) or (D)	Price	•	Transa	Reported Transaction(s) (Instr. 3 and 4)		(11150.4)	(11150.4)
Common Stock 11/29/					9/2019				F		4,678(1	(1) D \$2		\$21	73 172,777		D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) (Month/Day/Year) 3. Transaction Date (Month/Day/Year) (Month/Day/Year)			n Date,	4. Transaction Code (Instr. 8)		n of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		estr. 3			9. Number of derivative Securities Beneficially Owned Following Reported Transactions (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of Indire Benefici Ownersl ct (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)		Date Exercisa		Expiration Date	Title	or Nur of	ount mber ares						

Explanation of Responses:

1. Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.

Remarks:

/s/ Paul Brannelly as Attorney-12/02/2019 In-Fact For Joseph Ciaffoni

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.